LixiLan-O and LixiLan-L meet primary endpoints
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.
List view / Grid view
News
Researchers develop first vaccine against toxic shock syndrome
13 June 2016 | By Victoria White, Digital Content Producer
Researchers have developed the world's first safe and effective vaccine against toxic shock syndrome and successfully tested it in a Phase I trial...
New data for Trulicity and Tradjenta in type 2 diabetes
Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and Tradjenta (linagliptin) at the American Diabetes Association 76th Scientific Sessions.
Novo Nordisk presents new findings for Tresiba and semaglutide
13 June 2016 | By Victoria White, Digital Content Producer
Novo Nordisk presented new findings from separate studies of Tresiba and semaglutide at the American Diabetes Association 76th Scientific Sessions...
Merck to acquire Afferent Pharmaceuticals
10 June 2016 | By Victoria White, Digital Content Producer
Merck, known as MSD outside the US and Canada, has announced that it is is to acquire Afferent Pharmaceuticals...
Blincyto improves overall survival in B-cell precursor acute lymphoblastic leukaemia
10 June 2016 | By Victoria White, Digital Content Producer
Amgen's Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival compared to standard of care...
Replacing diseased immune system halts MS progression
10 June 2016 | By Victoria White, Digital Content Producer
A study shows that completely wiping out the immune system and then regenerating a new one can eliminate all signs of damaging brain inflammation in MS...
Turkish pharma grows by 15.6%, as CPhI Istanbul shares MENA trends and challenges for 2016
10 June 2016 | By CPhI
Key growth drivers for the MENA region were forecasted at CPhI Istanbul, with outsourcing, vaccine development and biotechnology emerging as major trends...
Study finds biosimilar switching not suitable for all patients
10 June 2016 | By Victoria White, Digital Content Producer
A study presented at EULAR showed that when antibodies develop in response to the infliximab, they also cross-react with the biosimilar of infliximab...
Long-term safety data for Revolade in adults with chronic ITP
10 June 2016 | By Victoria White, Digital Content Producer
Data from the largest study of its kind confirm the long-term safety profile of Novartis’ Revolade in adults with chronic immune thrombocytopenia...
Daratumumab significantly extends PFS in multiple myeloma study
10 June 2016 | By Victoria White, Digital Content Producer
A Phase III trial shows daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in the risk of disease progression or death...
Venetoclax shown to be effective in CLL patients who relapse or are refractory
10 June 2016 | By
New data show promising results for venetoclax in patients with chronic lymphocytic leukaemia who have relapsed or become refractory (R/R) to treatment...
Bimekizumab demonstrates positive results in patients with psoriatic arthritis
10 June 2016 | By Victoria White, Digital Content Producer
In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated...
New data for baricitinib in rheumatoid arthritis presented at EULAR
Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
Efficacy and safety of Biogen’s anti-TNF biosimilars presented at EULAR
9 June 2016 | By Victoria White, Digital Content Producer
Data demonstrating long-term comparable efficacy, safety and immunogenicity of Benepali (etanercept) and Flixabi (infliximab) have been presented at EULAR...
